NewAmsterdam Pharma
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Gooimeer 2-35, Naarden, Noord-Holland, 1...Phone Number
+31 352062971Website
www.newamsterdampharma.comRevenue
$22.6 MillionStock Symbol
NAMSIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
2
About NewAmsterdam Pharma
Based out of Naarden, The Netherlands, NewAmsterdam Pharma is a privately-held clinical-stage company with a focus on therapies for cardiometabolic diseases.Explore more
NewAmsterdam Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NewAmsterdam Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NewAmsterdam Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once NewAmsterdam Pharma has new funding data
Product Launch: Get notified when NewAmsterdam Pharma launches new products
Earning: See what the market has to say on NewAmsterdam Pharma recently announced quarterly report
Check out if NewAmsterdam Pharma is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at NewAmsterdam Pharma
NewAmsterdam Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if NewAmsterdam Pharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
NewAmsterdam Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NewAmsterdam Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NewAmsterdam Pharma.
NewAmsterdam Pharma financials insights
Gather financial insights about NewAmsterdam Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$196M
NewAmsterdam Pharma Tech Stack
A closer look at the technologies used by NewAmsterdam Pharma
Most Recent Scoops
Open Position
Open Position
Left Company
Executive Move
Douglas Kling, Chief Operating Officer, will be leaving the organization, effective August 14, 2026.
Executive Moves, Left Company
Open Position
Person-Based
Medical Research, Pharmaceuticals
NewAmsterdam Pharma News & Media
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’sNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe –NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analyNewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe -
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NewAmsterdam Pharma
Sign Up For FreeTo access detailed company insights
Based out of Naarden, The Netherlands, NewAmsterdam Pharma is a privately-held clinical-stage company with a focus on therapies for cardiometabolic diseases.... Read More
